Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 6/20 | 0.49 |
| ▸ | CCR5 | P51681 | 11/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.34 |
| ▸ | CCR7 | P32248 | 2/20 | 0.34 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7216664 | 0.95 | CCR2 (0.47) | CCR2CCR5L3MBTL1CXCR3CCR7 | |
| SCHEMBL7218136 | 0.95 | CCR2 (0.49) | CCR2CCR5L3MBTL1CXCR3CCR7 | |
| SCHEMBL7171409 | 0.92 | CCR2 (0.51) | CCR2CCR5CXCR3CCR7CXCR5 | |
| SCHEMBL7222495 | 0.92 | CCR2 (0.46) | CCR2CCR5L3MBTL1CXCR3CCR7 | |
| SCHEMBL7221638 | 0.92 | CCR2 (0.49) | CCR2CCR5L3MBTL1CXCR3CCR7 | |
| SCHEMBL7167251 | 0.91 | CCR2 (0.47) | CCR2CCR5L3MBTL1CXCR3CXCR5 | |
| SCHEMBL7215854 | 0.91 | CCR2 (0.51) | CCR2CCR5CXCR3CCR7NPC1 | |
| SCHEMBL7165818 | 0.90 | CCR2 (0.49) | CCR2CCR5L3MBTL1CXCR3CCR7 | |
| SCHEMBL7222727 | 0.90 | CCR2 (0.44) | CCR2CCR5L3MBTL1CXCR3CCR7 | |
| SCHEMBL7216597 | 0.90 | CCR2 (0.48) | CCR2CCR5L3MBTL1CXCR3CCR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6627651-B1 | Exhibiting preventive and therapeutic effects against HIV infectious diseases wherein R1 is an optionally substituted five- or six-membered ring group; X1 is a free valency or the like; W is a divalent group and inhibitors of HIV (human | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-09-30 | — | — | US | disclosed |
| US-20030078189-A1 | Medicinal compositions for oral use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1236476-A1 | MEDICINAL COMPOSITIONS FOR ORAL USE | Takeda Chemical Industries, Ltd. (JP) | 2002-09-04 | — | — | EP | disclosed |
| EP-1182195-A1 | CYCLIC COMPOUNDS AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078189-A1 | Medicinal compositions for oral use | CCR5, CXCR3, CCL5 | CCR2 23/4885CCR5 1/4885L3MBTL1 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.